Nationalwwwaaa13.com

TheImpactofMedicinesCorporateandSocialResponsibilityReport2002Domore,feelbetter,livelongerCorporateresponsibilityisanintegralpartofourbusiness–itisinherentinthemissionofourcompany.
GlaxoSmithKlinemakesasignificantpositivecontributiontosocietyaroundtheworld,throughthemedicinesandhealthcareproductsthatweresearch,develop,manufactureandsell.
ImpactofMedicinescoverstoryAlthoughagenerationseparatesthem,BettinaBartelsandhersonPhilippeareabletoleadactivelivesdespitebothsufferingfromasthma.
TheirstorycanbefoundinourAnnualReview.
Onpage5ofthisreport,DrVincentMcGoverngiveshisperspectiveonasthmamanagementasbothapatientandadoctor.
Contents01Aglobalchallenge02Thescopeofourbusiness04Ourcontributiontosociety06Medicinesforthedevelopingworld12Communityinvestment16Researchanddevelopment20Valuingpeople24Environment,healthandsafety28Businessethicsandintegrity32ManagementofCSR33WebreferencesAnnualReportAnnualReviewCorporateandSocialResponsibilityReportAglobalchallengeTheresponsiblebehaviourofalltypesoforganisations,includingmultinationalcompanies,governmentsandcharities,ishighonthepublicagendaandstimulatesconsiderabledebate.
Lastyear,inourfirstreviewofcorporateandsocialresponsibility,whichcoveredGSK'sfirstyearasanewcompany,wesetoutourcommitmenttoconnectingbusinessdecisionstoethical,socialandenvironmentalconcerns1.
Inthisreport,whichcoversactivityduring2002,wecovertheissuesthathavegeneratedsignificantinterestfromstakeholders.
Wehavemadegoodprogressthisyear,includingdevelopingindicatorsthatwillenableustoshowourprogressinaddressingtheseissues.
Wewillcontinuetobuildonthesestepstoincreasethetransparencyofouroperations.
Inthiswayweexpecttogiveourstakeholdersthesameconfidenceinthevalueofourbusinessthatwefeelourselves.
Corporateresponsibilityisanintegralpartofourbusiness–itisinherentinthemissionofthecompany.
GSKmakesasignificantpositivecontributiontosocietyaroundtheworld,throughthemedicines,vaccinesandhealthcareproductsthatweresearch,develop,manufactureandsell.
01Ourproductsmustimprovepeople'slivestoensureaprofitableandsustainablefutureforourbusiness.
Wealsounderstandthatitisnotjusthowmuchprofitwemakethatmatters.
Stakeholders,includingemployees,wanttoknowhowwemakethisprofit,andtobereassuredofthesoundethicalbasisforourbusiness.
Wecouldnotrunourbusinesseffectivelywithouttalkingwith,andlisteningto,themanygroupsourbusinessimpacts.
Discussionwithstakeholdersisapartofoureverydaywork.
Thisisverymuchatwo-wayrelationshipbecausetheviewsandexpectationsofstakeholdersdirectlyaffectus.
Weconsultwidely,bothformallyandinlessformalways.
Thediversityofourstakeholders,forexamplepatients,customers,healthcareprofessionals,governments,non-governmentalorganisationsandshareholders,inevitablygivesrisetoverydifferentandsometimesconflictingdemandsforustoconsider.
Wewillcontinueourconstructiveengagementtoguideusinrunningasuccessfulbusinessthatcontributestomeetingtheneedsofsociety.
SirChristopherHoggChairmanJPGarnierChiefExecutiveOfficerDuring2002,we.
.
.
investedatotalof239millioninglobalcommunityactivities,productdonationsandcharitablecontributions–morethananyotherUKcompany;donated66millionalbendazoletablets,worth8.
7million,to31countriestosupportthepreventionoflymphaticfilariasis;increasedshipmentsofourCombivirHIV/AIDStreatmentatpreferentialpricestothedevelopingworldtonearly6milliontablets,upfrom2.
2millionin2001;workedwithothercompaniestoestablishnewindustryPrinciplesontheConductofClinicalTrialsandCommunicationofClinicalTrialResults;andsurveyed10,000ofourmanagersontheirviewsofGSK'sSpiritandculture.
GlaxoSmithKlineresearches,develops,manufacturesandmarketsmedicinesandconsumerhealthproductsaroundtheworld.
02R&D–DISEASESOFTHEDEVELOPINGWORLDContinuingourcommitmenttofindpreventionsandtreatments,particularlyforHIV/AIDS,malariaandTB(page7)MEDICINESFORTHEDEVELOPINGWORLDFacilitatingaccesstomedicinesandimprovinghealthandeducationthroughpartnerships(page8)COMMUNITYINVESTMENTImprovingthequalityoflifeofunder-servedpeopleinthedevelopedanddevelopingworld(page13)ETHICALISSUESINR&DConsideringthequestionsthatarisefromtheresearchanddevelopmentofnewmedicinesandvaccines(page17)KeyimpactareasThescopeofourbusiness.
.
.
over100,000employeesoperatingin150countries,withmorethan20researchanddevelopmentcentresin8countriesandproductionfacilitiesin38countries.
commercialiseandsupporteffectivemarketingofprescriptionmedicines,vaccinesanddeliverysystemsforthetreatmentandpreventionofhumandisease.
Weemployover15,000staffinR&Dandhavemorethan20R&Dsitesworldwide.
Ourportfolioofproductsrangesfromtabletsandtoothpastetoinhalersandcapsules.
Wemakeover36,000differentpacksizesandpresentations.
Wehaveanetworkof95manufacturingsitesin38countriesandemploymorethan33,000inmanufacturingandrelatedsupportfunctions.
Eachyearweproduceoverfourbillionpacks,whicharedeliveredforsaleinover150countries.
Thepharmaceuticalindustryishighlyregulated,witheverystagefromdiscoverytosalesandmarketingcloselycontrolled.
Ourstakeholdersaremanyandtheirexpectationscanbeverydifferent.
Thus,sizeandcomplexitymakethisachallengingbusiness.
Thisraisesmanyquestionsaboutwhatwedo,andhowandwhywedoit.
Ourmainimpactsonsociety,andhowwemanagethese,aredescribedinthisreport.
202428SALESGlaxoSmithKlineThescopeofourbusiness03DEVELOPINGOUREMPLOYEESAttracting,rewardingandmotivatingpeopleinasafeandhealthyworkplace(page21)SUPPORTINGHUMANRIGHTSRespectingtherightsandinterestsofallthoseaffectedbyandinvolvedinourbusiness(page22)CARINGFORTHEENVIRONMENTUsingresourcesefficientlyandminimisingnegativeenvironmentalimpacts(page25)BUSINESSETHICSEnsuringouremployeesunderstandandimplementourCodeofConductandpoliciesforensuringethicalbusinesspractices(page29)GlaxoSmithKlineoperatesinthepharmaceuticalandconsumerhealthcaresectors,makingprescriptionmedicines,vaccines,over-the-countermedicines,oralcareandnutritionalhealthcareproducts.
Ourbusinessisfoundedprimarilyonresearchanddevelopmenttodiscover,develop,register,InformationonfinancialperformanceisavailableintheAnnualReportandAccounts.
USAPHARMACEUTICALS46%EUROPEPHARMACEUTICALS22%INTERNATIONALPHARMACEUTICALS17%CONSUMERHEALTHCARE15%SALES21,212mTRADINGPROFIT6,694m(BusinessPerformance)R&DSPEND2,900mFINANCIALPROFILE2002Themainactivityofourcompanyistodevelopmedicines,includingvaccines,thatmakeavaluablecontributiontosociety.
Thesemedicinessavelives,relievesuffering,andtreatandoftenpreventdisease.
Theyimprovethequalityoflifeofpatientsandtheircarers.
Theyalsoenablepeopletocarryonwiththeirlivesandoftenreducethecostofmanaginganillness.
OurcontributiontosocietyIndevelopedcountries,becauseoftheavailabilityofeffectiveantibioticsandvaccines,wenolongerexpectourchildrentobeatriskfrominfectiousdiseases.
Thechallengeistoextendtheseadvancestodevelopingcountries.
Thenumberofdiseaseswhereresearchhasproducedmajoradvancescontinuestogrow.
However,thereisstillmuchtodo.
Thechallengeforourcompanyistocontinuetomeetsociety'sexpectationsbydevelopinginnovativemedicinesthatenablepeopletolivelongerandhealthierlives.
ACCESSTOMEDICINESWealsowanttoplayapartinimprovingthehealthcareofpeoplewhocurrentlyhavelimitedaccesstoourmedicines.
Ourprogrammesindevelopingcountriesaresetoutonpage7.
IntheUS,wearehelpingtoimproveaccesstomedicinesforlow-incomeseniorcitizensandthedisabledwholackprescriptiondrugcoveragethroughpublicorprivateinsuranceprogrammes.
Inlate2001,GSKlaunchedtheOrangeCardSM,whichofferssavingsonthecompany'sprescriptionmedicines.
ThiswasthefirstprogrammeofitskindintheUS,withparticipantsrequiredsimplytopresentthecardtotheirpharmaciststoreceivethesavings.
Inaddition,lastyearGSK'sPatientAssistanceProgramprovidedmedicinesworthover112milliontomorethan400,000lowincomepatientsintheUSwhodonothavemedicalinsurance.
FollowingthepositiveresponsetotheOrangeCard3frompatients,doctors,andcompanies,GSKandsixotherpharmaceuticalcompanieslaunchedajointschemein2002.
TheTogetherRxCard4provideseligibleseniorcitizensandthedisabledintheUSwithasingle,easy-to-usecardtoreceivesavingsontheprescriptionmedicinesofthesevencompaniesinvolved.
TheseprogrammesarehavingarealimpactonthelivesofdisadvantagedpeopleacrosstheUS.
04Thepositiveeffectourmedicineshaveonpeople'slivesisoneofthefactorsthatmotivatesouremployees.
Thenatureofwhatwedogivesthemtheopportunitytomakeadifferencetothehealthofmillionsofpeoplearoundtheworld.
CHANGINGEXPECTATIONSWithadvancesinmedicine,societyhaschangeditsexpectationsofhealthcare.
Diseasesthatoncehadadevastatingimpactarenowcontrolledthroughimprovedhealthcaremanagementandwithbettermedicinesandvaccines.
Thishasledmanypeopleinthedevelopedworldtotakegoodhealthforgranted.
Forexample,agenerationagopoliowasoneoftheworld'smostfearedinfectiousdiseases.
Thankstotheworldwidevaccinationinitiativeco-ordinatedbytheWorldHealthOrganization2andtothemajorcontributionofourvaccinesbusiness,theglobaleliminationofpolioisinsight.
''GSKisopeningupthedoorforsignificantsavingstoanestimated10millionAmericans.
Thatwillmakeatremendousdifferenceinthelivesofsomanypeople.
''TommyThompsonUSSecretaryofHealthandHumanServicesonlaunchoftheOrangeCardCasestudyDRVINCENTMCGOVERN,AGENERALPRACTITIONERINBELFAST,UK,GIVESHISPERSPECTIVEONASTHMAMANAGEMENTASBOTHAPATIENTANDADOCTOR.
APatient'sPerspective–"Themanagementofasthmahaschangeddramaticallyoverthelast30years.
Iwasthechildwhowantedtoplayfootball,buthadtoplayingoal,whohadroundedshouldersandablueinhalerineverypocket.
Iremembersleeplessnightswithemergencyvisitsfromthedoctor.
Wheninhaledsteroidsbecameavailabletheytookawaythesleeplessnights.
Thedevelopmentofnewtreatmentshasmadeahugeimpactonmylife.
Istillhaveasthma,butit'swellcontrolledbypreventativetreatments.
Icertainlydon'tnoticeIhaveit,andnobodyelsedoeseither.
"Asthma-relateddeathsandhospitaladmissionshavedeclined,buttheincidenceofasthmaisgrowing.
Asthmaremainsamajorhealthissueworldwide.
Wefocusonwhatmatterstopatients,concentratingontheirqualityoflife.
051970sVentolin(bronchodilator)Relievesbreathlessnessfor3-6hoursperdose1970sBecotide/Beclovent(corticosteroid)Reducestheinflammationinthelungsthatleadstoasthmasymptoms1990sSerevent(bronchodilator)Relievesbreathlessnessforupto12hoursperdose1990sFlixotide/Flovent(corticosteroid)MoreeffectivelyreducestheinflammationinthelungsthatleadstoasthmasymptomsTodaySeretide/Advair(bronchodilator/corticosteroid)Thefirstasthmaproductthatrelievesbreathlessnessforupto12hoursperdoseandreducestheinflammationthatleadstoasthmasymptoms,inoneeasytousedevicefffffDEVELOPMENTOFOURASTHMATREATMENTSADoctor'sPerspective–"AsaGPwhoisalsoanasthmatic,Ifindasthmaareallysatisfyingconditiontotreat.
Itiscommon,with5.
1millionsufferersintheUK.
Inmypractice,80percentoftheasthmaticswillhavemild-to-moderatedisease.
Iaimtoachievetotalcontroloftheirsymptomsusingcurrenttreatments,givingthemagoodqualityoflife.
Andthestandardofpatientcareisgettinghigher,eitherthroughspecialisedunitsorone-to-oneconsultationswithnursesordoctors.
Asthmaisanareawherenationaltreatmentguidelineshavebeenadoptedandhavehadamajorimpactondiseasemanagement.
"Overthelast30yearsourR&Dorganisationhasproducedimprovedmedicinestotreatasthmaandbetterwaysforthemtobetaken.
Theseadvanceshavebeenvitalinenablinghealthcareprofessionalstoprovideever-improvingpatientcare.
However,asthmastillcausessufferingandevendeath,sowewillcontinueourresearchwiththeaimoffurtherimprovingthelivesofthegrowingnumberofpeopleaffectedbythisdisease.
Indevelopingcountries,millionsofpeoplelackaccesstothemostbasichealthcareservices.
Life-threateningdiseasessuchastuberculosis,malariaandHIV/AIDSarecontributingtoahealthcarecrisis.
06MedicinesforthedevelopingworldTheglobalcommunitymustprovidepoliticalwill,asignificantmobilisationofadditionalresources,andaspiritofpartnershipifwearetoseeanimprovementinhealthcareandqualityoflifeacrossthedevelopingworld.
GlaxoSmithKlineismakingavitalcontributiontohealthcareindevelopingcountriesthroughactioninthreeareas:investinginresearchanddevelopment(R&D)thattargetsdiseasesparticularlyaffectingthedevelopingworld;preferentialpricingofourantiretrovirals,anti-malarialsandvaccines;andcommunityinvestmentactivitiesandpartnershipsthatfostereffectivehealthcare5.
Wemadesignificantadvancesineachofthesekeyareasduring2002.
R&DFORDISEASESOFTHEDEVELOPINGWORLDResearchintodiseasesofthedevelopingworld(DDW)isparticularlyimportanttoaddressunmetneeds,andtominimisetheintrinsicthreatinallinfectiousdiseasesofresistancedevelopingtoexistingtreatments.
AdedicatedDDWgrouphasbeencreatedwithinGSK'sR&Dorganisationtoensureafocusonthisarea.
Projectsareprioritisedprimarilyontheirsocio-economicandpublichealthbenefitsratherthantheircommercialreturns.
OurDDWresearchisnowfocusedindedicatedfacilitiesatTresCantosinSpain(seepage11).
WebelieveGSKhastheindustry'smostextensiveportfolioofDDWR&Dprojectsandmarketedproducts,andthatwearetheonlycompanyundertakingR&DintothepreventionandtreatmentofallthreeoftheWorldHealthOrganization'sprioritydiseasesinthedevelopingworld–HIV/AIDS,tuberculosisandmalaria.
GSKfocusesonthesethreediseases.
Wearealsoanindustryleaderincollaboratingwithexternalpartnersthatwanttouseourspecialistinfrastructureorexpertise.
R&Dintodiseasesthatprimarilyaffectthedevelopingworld,suchasmalaria,differsinimportantrespectsfromeffortsaimedatdiseasesforwhichadevelopedworldmarketalsoexists,suchasHIV/AIDS.
ThelackofacommerciallyviablemarketforDDWtreatmentsmeansthatpublic/privatepartnershipsareessential.
MajorcompaniessuchasGSKcanprovidetechnological,development,manufacturinganddistributionexpertise,whilepublicsectorpartnerscanhelpfunddevelopmentcostsandensurethatnewmedicinesandvaccinesgettothepeoplewhoneedthem.
ThepartnershipapproachencouragesR&Dandacceleratestheproduct'suptakeinthedevelopingworld.
07HIVZiagen/EpivircombinationRetrovirEpivirCombivirZiagenTrizivirAgeneraseproteaseinhibitor*S.
pneumoniaepaediatricHavrix(hepatitisA)EngerixB(hepatitisB)Twinrix(hepA&B)Infanrix(diptheria,tetanus,acellularpertussis)Tritanrix(diptheria,tetanus,wholecellpertussis)PolioSabin(polio)Priorix(measles,mumpsandrubella)Typherix(typhoid)Hiberix(haemophilusinfluenzaetypeb)VaccinestafenoquineMalaroneHalfanLapdap*MalariasitamaquineoxibendazoleTBPHASEIIIMARKETEDPHASEINNRTIproteaseinhibitorintegraseinhibitorHIVDenguefeverHepatitisERotavirusMeningitisBMalariaN.
meningitidisCDAPHASEIIPRE-CLINICALACTIVITYZiagen/EpivircombinationS.
pneumoniaepaediatrictafenoquinePHASEIIIsitamaquineoxibendazoleZentelOthersitamaquineoxibendazole*beingregisteredandnotyetmarketed.
DDWDEVELOPMENTPIPELINEatendof2002WewillmaintainbroadlythecurrentlevelofhumanandfinancialresourcesdedicatedtoDDWasaproportionofourtotalR&Dinvestment.
Wewillworkassiduously,withpartnerswhenappropriate,toensurethatanypromisingDDWdrugismadeavailabletopatientsasrapidlyaspossible.
TheR&Dprocessislengthyandrisky.
However,ourlong-termcommitmentisnowbearingfruitandwearehopefulthatwewillbeabletolaunchseveralnewproductsrelevanttoDDWoverthenextfiveyears.
Wehaveseensomenotableprogressin2002.
InHIV/AIDSthefirsthumanclinicaltrialsofourHIVcandidatevaccinecommencedinFebruary,incollaborationwiththeUSGovernment'sNationalInstitutesofHealthHIVVaccineTrialsNetwork6.
Inconjunctionwithotherpartners,GSKcontinuestosupport29HIVclinicaltrialsindevelopingcountries,including20inAfrica.
Thepurposeofthesetrialsistoassesstheuseofantiretroviraltherapyfortreatment,andpreventionofmother-to-childHIVtransmissioninresource-poorsettings.
Over10,000patientsformorwillformpartofourHIVcollaborativestudies.
ThreethousandofthesepatientswillbeincludedintheDARTTrial(DevelopingAntiretroviralTherapy)inUgandaandZimbabwe,co-ordinatedbytheUKMedicalResearchCouncil.
Therehasbeenprogressinmalariatoo.
InOctober2002,wesubmittedaregulatoryapplicationtotheUKMedicinesControlAgency(MCA)forLapdap(chlorproguanil/dapsone)forthetreatmentofthemostlifethreateningtypeofthemalaria.
MCAapprovalwillbeanimportantstepinmakingLapdapavailableacrossAfrica,wherethereisgreatneedfornewmalariatreatments.
LapdapresultsfromasuccessfulpartnershipbetweenGSK,theWorldHealthOrganization,theUniversityofLiverpool,theLondonSchoolofHygiene&TropicalMedicine,andtheUKDepartmentforInternationalDevelopment(DFID)7.
ThisisthefirstsuchproductdevelopmenttobedirectlysponsoredbyDFID.
PREFERENTIALPRICINGGSKrecognisesthatithasaresponsibilitytomakeitsproductsasaffordableaspossibleinthepoorestcountries.
Wehaveofferedourvaccinestopublichealthprogrammesatsignificantdiscountsforover20years.
Wesetasingle,sustainable,not-for-profitpreferentialpriceforeachofourantiretrovirals(ARVs)andanti-malarialstoawiderangeofcustomersintheLeastDevelopedCountriesandsub-SaharanAfrica–atotalof63countries.
Thesecustomersincludethepublicsector,not-for-profitNGOs,aidagencies,UNagencies,andinternationalpurchasefundssuchastheGlobalFundtofightAIDS,TBandMalaria.
Wealsoextendourofferofnot-for-profitpricesonARVstoemployersinsub-SaharanAfricawhoprovidecareandtreatmentthroughworkplaceclinicsandsimilararrangements.
GSKiscommittedtocontributingtohealthimprovementsinasustainablemanner,sowesetourpreferentialpricesforARVsandanti-malarialsatlevelsthatcoverdirectcostsbutonwhichwedonotmakeaprofit.
Inthiswaywecanofferthesepricesforaslongaspatientsneedtreatment8.
Ourlong-termcommitmentisnowbearingfruitandwearehopefulthatwewillbeabletolaunchseveralnewproductsrelevanttoDDWoverthenextfiveyears.
08NUMBEROFSUPPLYARRANGEMENTSFORARVsANDTYPEOFCUSTOMER140120100806040200Q4Q1Q2Q3Q4Q1Q2Q3Q4Q12000200120022003EmployersPublicHospitalsKeyNGOsGovtNonAAIAAI(AcceleratingAccessInitiative)Special'Access'packsSupplyarrangements09Wehavepledgedtopassoncostefficienciesasshipmentstothedevelopingworldincrease.
Forinstance,inSeptember2002,wefurtherreducedthenot-for-profitpreferentialpricesofourHIV/AIDSmedicinesbyupto33percentandouranti-malarialmedicinesbyupto38percent9.
Bytheendof2002,wehadsecured124arrangementstosupplypreferentially-pricedARVsto50countries.
Thisincludes49arrangementsmadeduring2002.
Thesearrangementsarewithawiderangeofstakeholders,includinggovernments,NGOs,publichospitalsandemployerssuchasHeinekenandAngloAmerican,withwhomwecommencedpartnershipsin2002.
Asaresult,weincreasedshipmentsofCombivirtothedevelopingworldfrom2.
2milliontabletsin2001tonearly6milliontabletsin2002–theequivalentofabout3milliondailydoses.
ThesefiguresexcludetheproductdestinedforpatientsinAfricawhichwasdivertedbacktoEurope.
ThevictimsofthistradeareHIV/AIDSpatientsinAfricaandtheonlybeneficiariesaretheillegalimporters.
GSKhasintroducedspecial'Access'packstomakethisillegaltrademoredifficult.
Welooktoregulatoryauthoritiesandourcustomerstoalsotakemeasurestopreventdiversion.
GSK'sabilitytoprovidepreferentialpricestothedevelopingworldrequiresasustainableframework.
Ourcommitmenttopreferentialpricingmustbecombinedwithcommitmentsfromotherstopreventproductdiversionandtoavoidreferencingdevelopedcountrypricesagainstpreferentially-pricedmedicines.
Clearlydiversionthreatensthisframework.
Additionally,in2002,westartedsmall-scaleshipmentsofawiderrangeofpreferentially-pricedproductstothefivepilotprojectswehaveinpartnershipwithNGOsinTanzania,Uganda,Nigeria,ZambiaandMalawi.
Theseprojectsaredesignedtoassesstheimpactofpreferentialpricingforabroaderrangeofproducts.
COMMUNITYINVESTMENTPROGRAMMESWehaveawiderangeofpartnershipsinthedevelopingworld.
Ourfocusisonhealthandeducationprogrammesforunder-servedcommunitiesaroundtheworld10.
In2002,GSKinvestedover12millioninitspublichealthprogrammes.
OurpartnersrangefromtheWorldHealthOrganizationandtheWorldBanktolocalschoolsandcommunity-basedorganisations.
Wherepossible,weensurethatourprogrammesaresustainableandcanberepeatedincommunitieswithsimilarneeds.
Ourprogrammescomprisemajorinitiativesinpublichealth,supportforeducation,productdonations,andsupportforemployeeinvolvementactivities.
Ourpublichealthprogrammes,forexample,include:TheGlobalAlliancetoEliminateLymphaticFilariasis–GSKisakeypartnerintheglobalefforttoeliminatelymphaticfilariasis(LF),alsoknownaselephantiasis.
Thisisadisablinganddisfiguringdiseasethatcurrentlyaffects120millionpeople,andthreatensafurtheronebillion,insomeofthepoorestnationsoftheworld11.
CUMULATIVESHIPMENTSOFCOMBIVIRTABLETS(EXCLUDINGDIVERTEDPRODUCT)9876543210Q1Q2Q3Q4Q1Q2Q3Q420012002TabletsShipped(millions)GSKisafoundingmemberofthepartnershipthatincludestheWorldHealthOrganization,theMinistriesofHealthoftheLF-endemiccountries,and40organisationsinthepublic,privateandacademicsectors.
GSKdonatesitsantiparasiticdrugalbendazole,oneofthreedrugsusedtostoptransmissionofthedisease.
Overtheanticipated20-yearlifeoftheprogramme,thiscommitmentwillbuildtoanestimatedsixbilliontabletsasmorecountriesjoin.
Inaddition,weprovidesignificantfinancialresourcesandstaffexpertisetosupportcoalition-building,advocacy,research,communitymobilisation,andeducationalinitiatives.
In2002,thefourthyearoftheprogramme,66milliontablets(worth8.
7million)weredonatedto31countries,bringingthetotalnumberofalbendazoletabletsdonatedtodateto145million.
Grantstotalling750,000werealsomade.
AhugemobilisationofeffortisrequiredforthefightagainstLF.
Thisisexemplifiedbythemorethan45,000healthworkersandvolunteersinSriLankawhoworkedtogethertodeliverpreventativemedicinesto9millionpeopleinasingledayinJuly2002.
PositiveActionprogramme–In2002,GSK'sinternationalprogrammeofHIVeducation,careandcommunitysupport,backed25internationalprogrammesin32countries12.
ActivitiesfundedbyPositiveActionsupportthetwo-year'LiveandLetLive'WorldAIDSCampaignlaunchedbyUNAIDSonWorldAIDSDay2002.
Forexample,PositiveAction-fundedstudiesbytheInternationalCenterforResearchonWomen,conductedinEthiopia,TanzaniaandZambia,haveconfirmedthatsocietaldiscriminationbasedonHIVfuelsthespreadofAIDS.
PositiveActionalsoannouncedfundingfornewcommunityinitiativesinKenyaandMexico13.
Duringthe14thInternationalAIDSConference,heldinBarcelonainJuly2002,PositiveActioncontributedover90,000tosupportattendanceandparticipationofcommunityrepresentativesfromunder-resourcedregions.
TheGSKFranceFoundation–supportsprogrammesthatpreventtheriskofverticaltransmissionofHIV;providemedicalcare,monitoringandtreatment;andimproveaccessandqualityofcareforpeoplelivingwithHIV.
In2002,theFoundationsupported13programmesinvolving42,000peopleaspartofafouryear1.
3millioncommitmentineightAfricancountries14.
AfricanMalariaPartnership(AMP)–inNovemberthreeorganisationswereselectedtosharegrantstotalling1.
0millionoverthreeyearsundertheAMP.
Throughthisprogramme,GSKisfundingbehaviouraldevelopmentinitiativestocombatadiseasethatkillsoveronemillionpeopleeveryyear.
Intotalnearlytwomillionpeoplewillbereachedbytheprogrammesinthesevencountriesinvolved15.
10OurpartnersrangefromtheWorldHealthOrganizationandtheWorldBanktolocalschoolsandcommunity-basedorganisations.
1999200020012002Millions806040200Years"GlaxoSmithKlinehasmuchtobeproudofinimprovinghealthcareinthedevelopingworldthroughitsdrugdistribution,researchanddevelopment,andcommunityactivities.
Theworld'sattentionisfocusedonprivatecompaniesandgovernmentsasweworktogether.
"ConstanceA.
CarrinoDirector,OfficeofHIV/AIDS,USAIDEstimatedpatientstreated(m)Tabletsdonated(m)KeyLFELIMINATIONPROGRAMME145millionalbendazoletabletsdonatedtodateCasestudyGSK'sTresCantossitehousesmajorelementsofourR&Dhigh-throughputscreeningactivitiesandGSK'scommercialoperationsinSpain.
However,wehavenowalsoconcentratedourDDWdrugresearchinTBandmalaria–effortswithalonghistoryinGSK–intodedicatedfacilitiesonthesite,withafull-timeresearchstaffcommittedsolelytoDDW.
Aswellasthecentre'sTBandmalariafocus,ideasanddrugcandidatesfortreatingotherneglecteddiseasesofthedevelopingworldarepursuedopportunistically,andthedevelopmentofexistingGSKdrugcandidatesforsuchdiseaseswillcontinue.
TheTresCantosDDWscientificstaffprovidethewiderangeofskills–includingchemistry,biologyandtoxicology–neededtobetterunderstandthediseasetargetsandidentifynoveldrugcandidatesforfurtherdevelopment.
SuchaconcentrationofresourcesandskillsmaximisesourabilitytodiscovernewmedicinesforDDW.
TheTresCantosgroupisfullyintegratedwiththerestofGSK'sR&Dinordertoensurethatwecanbringalltherelevantskills,technologiesandresourcestobeartoachievesuccessindevelopingsuchdiscoveries.
Inthisregard,GSK'sadvantagesofscaleandournetworkswithkeyexternalpartnersareimportant.
Inparticular,accesstoGSK'sworld-wideclinicaldevelopmentorganisationisvitalfortheeffectiveconductofclinicaltrials.
However,theDDWgroupatTresCantos,anditsassociatedDDWdrugdevelopmentteaminLondon,canalsocallonGSK'sexpertiseandstaffinmanyotherareas,suchasscreening,pre-clinicaldevelopmentandregulatoryaffairs.
11GSK'sresearchintoDiseasesoftheDevelopingWorld(DDW)iscentredondedicatedR&DfacilitiesinTresCantos,Spain.
ThisisinadditiontoourHIV/AIDSandvaccinesR&Dprogrammes.
Thetotalvalueofourcommunityinvestmentactivitiesin2002was239million.
12ProjectHOPEairliftofGSKantibioticstoTajikistan.
Ourproductdonationsforhumanitarianreliefreached73countriesin2002.
Weworkwithpartnerorganisationsaroundtheworldtoensurethattherightblendofexpertiseisappliedtoeachofourprogrammes,andweselectpartnerswhohavethebestexperienceandskillsforeachinitiative.
Programmesareselectedonthebasisofcommunityneed,notfortheirpotentialimpactonGSK'scommercialbusinessortoincreasesalesofourproducts.
Wefundprogrammesthataremeasurable,sustainableandreplicableandweworkcloselywithourpartnerstoensuretheirsuccess16.
WORLDWIDECOMMUNITYCONTRIBUTIONGSK'scommunityinvestmentandcharitablecontributionsin2002totalled239million,ofwhich112millionwasrelatedtothecompany'sPatientAssistanceProgramforfinanciallydisadvantagedpatientsintheUS.
Ourcorporateregionalpublichealthandhumanitarianreliefprogrammesaimtoservecommunitieswiththegreatestneeds.
TomeetlocalneedsGSKoperatingcompaniesalsosupportnumerouslocalcommunityprogrammes.
GSKproductdonationsforhumanitarianreliefaremadethroughcharitablepartnerorganisationsthathaveexperienceindeliveringhumanitarianrelief.
Thesecharitiesdecidewhereandwhenourproductdonationsaremostneeded,andworkwithgovernmentsofrecipientcountriestoensurethattheyarrivesafelyandaredistributedappropriately.
Forexample,adonationofalmosthalfamilliontreatmentsofourantibioticAugmentinwaspartofanairliftofvitalmedicinesintoTajikistaninOctober2002organisedbyProjectHOPE17.
Alreadystrugglingtoovercometheeffectsofcivilwar,TajikistanhasbeenfurtherchallengedCommunityinvestmentThefocusforGlaxoSmithKline'scommunityinvestmentsisonimprovinghealthandeducation.
Ourprogrammesextendtoboththedevelopedanddevelopingworld,andmostofoureffortsaretargetedatimprovingthequalityoflifeofpeopleinunder-servedcommunities.
byadecadeofsteadyimmigrationofrefugeesfromAfghanistan.
AsamemberofthePartnershipforQualityMedicalDonations,GSKhasfullyendorsedandagreedtofollowtheWHOGuidelinesforDrugDonations18.
Ourpublichealthprogrammesaredirectedtoareaswherespecificdiseasesareprevalent.
ThismeansthatourHIV/AIDScommunityprogramme,PositiveAction,hasglobalreach;ourefforttoeliminatetheparasiticdisease,lymphaticfilariasis,isfocusedonendemiccountriesinthedevelopingworld;andourAfricanMalariaPartnershipisdirectedtothecontinentthatbearsthegreatestburdenofthedisease(seepage10).
Inthedevelopedworldtoo,ourcommunityprogrammessupportcommunitiesinneed.
OurSHAREprogrammeintheUSandCanadatargetshealthinelderly,racialandethnicminoritycommunities.
Weareprovidingmonetaryawardsforinnovationandsharingbestpracticeonreducinghealthinequalityamongthesevulnerablegroups19.
13Wefundprogrammesthataremeasurable,sustainableandreplicableandweworkcloselywithourpartnerstoensuretheirsuccess.
14In2002,theInternationalBusinessLeadersForumAwardforInternationalCorporateCitizenshipwasmadetoGSKforourPHASEprogrammewhichprovideshygieneeducationforschoolchildren.
"Asacharity,PlanUKhasbeenveryimpressedbyGSK'sapproachtopartnership.
Theyhavebeenwillingtoconsultwithlocalcommunities,todevelopmaterialswhichareeasytouse,relevanttolocalcultureandsavechildren'slives.
"MarieStauntonExecutiveDirectorofPlanInternational"ThePHASEprogrammeismakingarealdifferencetothehealthandwell-beingoflocalcommunitiesandisanexcellentexampleofthepositiverolethatbusinesscanhaveinsociety.
"RobertDaviesChiefExecutiveoftheInternationalBusinessLeadersForumIntheUK,aspartofabroadcommitmenttoscienceeducation,wehavecommittedupto1millionoverfouryearstofundINSPIRE(INnovativeSchemeforPost-docsInResearchandEducation),aprogrammetoboostscienceeducationinschools20.
ThissupportsselectedschoolsapplyingtobecomeScienceCollegesundertheUKgovernment'sSpecialistSchoolsProgramme.
GSKprovidessupportinmanydifferentways,forexample,throughdonatingmoney,products,andotherin-kinddonationssuchasofficefurniture,computersandsurpluslaboratoryequipment.
OurproductdonationsarevaluedatwholesaleacquisitioncostwhichrelatestothepriceGSKchargeswholesalersandwarehousingchains,nottheretailprice.
ThecompanyfollowstheLondonBenchmarkingGroup21modelofrecordingourcommunityinvestments.
Thisrecognisedmodelprovidesastandardbasisforcompaniestomanageandreporttheircommitmentstothecommunity.
METHODOFGIVING(includingUSPatientAssistanceProgram)Cash42%PublicHealthProgrammes(includingLF)10%ProductDonations12%CorporateandRegionalProgrammes11%LocalProgrammes67%TYPEOFPROGRAMME(excludingUSPatientAssistanceProgram)InKind1%Product57%CasestudyIn1998GSKlaunchedaninitiativecalledPHASE–PersonalHygieneAndSanitationEducation–toprovidehygieneeducationforschoolchildren,withtheaimofreducingdiarrhoea-relateddiseaseanddeathsassociatedwithpoorhygiene.
PHASEstartedinpartnershipwithAMREF(AfricanMedicalandResearchFoundation)andoperatesinKenya,NicaraguaandPeru,whereGSKhascommitted1.
2millionforitsroll-out.
InLatinAmerica,GSKworkswiththechild-focuseddevelopmentcharityPlanInternational.
InKenya,83,000childrenin247schoolsarebenefitingfromthisbasiceducation,whileinNicaraguaitwillreachover27,000primaryschoolchildrenand20,000inPeru.
PHASEempowerschildrenandtheirfamiliestotakeresponsibilityfortheirownhealthandsanitation.
Communitiesaroundtheparticipatingschoolshavealsobenefited,withmosthomesnowhavingcontainersforhandwashing,pitlatrinesandrefusepits.
EvaluationoftheKenyanprogrammehasshownthat,asaresultofPHASE,childrenhaveabetterunderstandingofthecausesofdiarrhoeaandworminfestations,andknowaboutwaystopreventinfection.
Teachershaveseenimprovementsinschoolattendanceandreportthatchildrenarenowmuchcleanerandtakebettercareoftheirpersonalhygiene.
Datafromoneclassshowthatthepercentageofchildrenwhoknewthatwashinghandsaftergoingtothetoiletcouldpreventwormsincreasedfrom20percentbeforePHASEto45percentafterwards.
ThesuccessoftheprogrammehasbeensuchthattheKenyangovernmenthasincorporatedPHASEintothenationalcurriculum,increasingthelikelihoodofthesebenefitsbeingavailabletootherpartsofKenya.
Awiderangeofseriouslydebilitatingandlife-threateningdiseasesthriveinthepoorlivingconditionsfoundinmanycountriesofthedevelopingworld.
InAfricaalone,over3.
5millionchildrendieeachyearfromdiarrhoealdisease.
15Weunderstandtheneedtobalancethebenefitsthatpatientsgainfromnewmedicineswithanyrisksorethicalconsiderationsrelatingtonewtechnologies.
16Ifweareunabletotakeadvantageofadvances,patientswillnothavethebesttreatments.
WeunderstandconcernsabouttechnologicaladvancesintheR&Dprocess,andwelcomeinformeddebate.
TheR&Dprocessishighlyregulated,whereverweoperate.
Asscientificadvancesraisenewissues,weworkcloselywiththeregulators,policymakersandstakeholderstodevelopanyneworrefinedstandards.
Wehaveourowninternalstandardsandsystemstoensurethatwecomplywithorexceedallguidelines,regulationsandlegalrequirements.
THEESSENTIALROLEOFANIMALRESEARCHBasicresearchusinganimalsisvitaltofurtheringourunderstandingofhumandisease.
Animalstudiesalsoprovideanessentialbridgebetweencharacterisingpotentialnewmedicinesandvaccinesinthelaboratoryandlearningabouttheireffectsinpeople.
Bylaw,wemustassessdrugsafetyinanimalsbeforestartingclinicaltrials.
WearecommittedtothethreeRs–toreduce,refineandreplaceanimalstudies–andsetstringentstandardsinternallyandforourexternalcontractors.
WeensurethatallGSKstaffconductinganimalstudiesarethoroughlytrained.
Wereducethenumberofanimalsusedinresearchwhereverwecanwithoutcompromisingthesafetyofvolunteersandpatientsinclinicaltrials,andweseekasmuchinformationaspossiblefromeachanimalstudy.
ThenumberofanimalsusedinourlaboratorieshasthereforeremainedessentiallyconstantoverthelasteightyearsinspiteofasignificantincreaseinourR&Dactivity(seechart,page18).
Weuseanimalsmorehumanelybyusing,forexample,non-invasiveimaging(seepage19).
Researchanddevelopment17WeencouragestafftodevisealternativeapproachestoanimalresearchthroughinternalAnimalWelfareAwards.
GSKsponsorsthelargestEuropeanawardinthisfield–theGSKLaboratoryAnimalWelfarePrize22.
Inspectionsbynationalregulatoryauthoritiesacknowledgethehighstandardsofcareandcomplianceinourfacilities.
Toensurethatwemeetbestpractice,ourUSandUKanimalfacilitiesareaccreditedbytheAssociationforAssessment&AccreditationofLaboratoryAnimalCare23,andweareworkingtoextendthistoourotherfacilities.
Webelievethatthebestwaytoaddresspublicinterestinanimalresearchistofostergreaterknowledgeandunderstandingofthefacts.
Wealsobelievethatthisisthemosteffectivewaytohelpcombattheclimateoffearandintimidationbeingpromotedbyanimalextremistgroups.
Wethereforeprovideinformationtosupportrationalpublicdebate,activelyparticipateinsuchdiscussionsourselvesandhosttoursofouranimalfacilitieswherepossible.
Wealsowelcomegovernmentactionstoprotectourstaff,laboratoryanimalsandresearchcollaboratorsfromextremistactions.
Wevisitschoolstodiscussrelevantethicalissues,forexample,involvingover2000UKpupilsinsuchdiscussionsinthe2001-2schoolyear.
InformationonGSK'suseofanimalsinresearchisavailableonourwebsite24.
GlaxoSmithKlineaimstoproducesafeandeffectivemedicinesandvaccinesthatbenefitpatientsbyaddressingtheirunmetmedicalneeds.
Todothis,weneedtousethemostrecentadvancesinscienceandtechnologytounderstanddiseasesandtoidentifyandtestdrugs.
THE"THREERS"INANIMALRESEARCHReducethenumberofanimalsusedinmedicinesR&Dtotheminimumpossibletoobtainmeaningful,validatedresults.
Refineanimalexperimentalprocedurestoavoidorminimisepainordiscomfort,andtomaximisetheinformationobtainedfromeachstudyandeachanimal.
Replacetheneedforanimalstudiesbydevelopingandvalidatingalternativeapproacheswhereverfeasible.
REDUCEREFINEREPLACEWeareobligedbylawtoassessdrugsafetyinanimalsbeforestartingclinicaltrials.
TESTINGNEWMEDICINESINCLINICALTRIALSGSK'saim,todevelopmedicinesandvaccinesthatbenefitpatients,isreflectedintheprioritywegivetoprotectingtheinterestsofhealthyvolunteersandpatientswhotakepartinourclinicaltrials.
Theregulatoryauthoritiesrigorouslyscrutinisetheinitiationandconductofclinicaltrialsandrelatedactivities.
Theneedtorespecttherights,dignity,safetyandwell-beingofclinicaltrialparticipantsisenshrinedindeclarationsandguidelinesproducedbytheWorldMedicalAssociation,WorldHealthOrganization,CounciloftheInternationalOrganisationsofMedicalSciences,CouncilofEurope,theInternationalConferenceonHarmonisation(ICH)andgovernmentbodies.
GSKfullycomplieswiththerelevantregulationsandnationalrequirements,andwithguidelinessuchasICHGoodClinicalPractice.
Whenregulationsandguidelinesareperiodicallyreviewedandrevisedtoensurethattheyfullyaddresstheinterestsofpatients,GSKactivelycontributestothediscussionsonthebasisofourextensiveglobalexperience.
Inourlastreview,wesummarisedourrigorousprocedurestoensurepatientsafetyandtheprivacyoftheirmedicalinformation.
WehaverecentlystrengthenedprocedurestoavoidinformationbeingsenttoGSKbyexternalinvestigatorsthatwouldenableustoidentifytrialparticipants.
However,weknowthattheconductofclinicaltrialsraisesethicalissuesandwethereforeworkedwithothercompaniesin2002toestablishthenewPhRMAPrinciplesontheConductofClinicalTrialsandCommunicationofClinicalTrialResults25.
ThePrinciplesreflecttheimportanceofindependentInstitutionalReviewBoardsorEthicalReviewCommitteesinprotectingpatientsandvolunteersinvolvedinclinicaltrials.
GSKfullysupportstheseguidelines,whichreiteratetheneedtoobtaingenuinelyinformedconsentbeforeanyclinicalprocedureisundertaken,anobligationthatGSKextendstoincludeacquiringandusinghumanbiologicalsamplessuchastissuesandDNA.
ThePrinciplesalsosummarisethesafeguardstheindustry,includingGSK,adoptstoensurethatthereimbursementofpatients'andexternalclinicalinvestigators'expensesisnotaninappropriateinducementtoparticipateinclinicaltrials,ortobiastheresultsthatarereported.
Regulatoryauthorities'requirementsforfinancialdisclosurefurtherprotectthepublicinterestinthisarea.
ThePrinciplesarticulatetheindustry's,andGSK's,practiceofseekingtopublishthemeaningfulresultsofcontrolledclinicaltrials,regardlessoftheoutcome,inatimelymanner.
Thisincludesgivingclinicaltrialiststheappropriatelevelofaccesstotherawdataandtheirinterpretation.
18Rapidtechnologicaladvanceshaveprovideduswiththetoolstomakemajorprogressinthefightagainstdisease.
19941995199619971998199920002001%changesince1994Years200150100500CHANGEINR&DACTIVITYCOMPAREDWITHCHANGEINNUMBEROFANIMALSUSEDBYGSKAnimalsusedR&DactivityFiguresnormalisedto1994levelsKeyCasestudyREFININGRESEARCHUSINGANIMALSWhenstudyingadiseaseortheeffectofadrugoveraperiodoftime,animalswouldpreviouslyhavehadtobehumanelykilledandtheorgansremovedformicroscopicexaminationateachtime-point.
MRIenablesthesameanimaltoberepeatedlyassessedateachtime-pointsothenumberofanimalsusedisreduced.
Moreover,wecangetmoredetailedinformationabouttheprogressofadiseasebymorefrequentscanningthanwouldbepossibleifeverytime-pointneededaseparategroupofanimalsandresource-intensivetechnologiessuchasmicroscopicexamination.
Importantly,eachanimalcanoftenbeusedasitsowncontrolsothestatisticalpowerofthesestudiesisenhancedevenwhenusingfarfeweranimals.
19SerialMRIallowsrespiratorybiologiststostudylunginflammationinratsthatmimicssomeaspectsofhumanasthma.
Thesameanimalsarescanned,minimisingdiscomfort,forseveralweeks.
Thisallowschronicinflammatoryandotherresponsestobestudied,andthebeneficialeffectsofstandardandnewdrugstobemeasured.
TheMRIapproachtypicallyrequires24animalsforastudythatwouldrequiremorethan500ifundertakenusingconventionalmicroscopyapproaches.
Similarapproachesarebeingtakeninourotherresearchareas,suchasneurology,psychiatryandcardiovasculardiseases,aswellasinpreclinicalsafetyassessment.
Thecumulativebeneficialimpactonthenumberofanimalsusedandondataqualityisthereforeverysignificant.
Non-invasiveimagingtechniquessuchasmagneticresonanceimaging(MRI)canprovidenewandmorerelevantscientificinformationinwaysnotpreviouslypossible.
GSKemploysover100,000peopleandoperatesinmorethan150countries.
20Wearecommittedtoprovidingtheopportunityforouremployeestodomeaningfulandchallengingworkinpursuitofourgoaltoimprovethequalityofhumanlifebyenablingpeopletodomore,feelbetterandlivelonger.
Lastyearwereportedontheprinciplesthatunderpinourapproachtopeoplemanagement,andarangeofprogrammeswhichweredesignedtodeliverourglobalhumanresourcesstrategy.
Wearenowpleasedtoreporttheprogresswehavemadeandsetout,whereweareable,howweintendinfuturetomeasureourperformanceonissuessuchasdiversity.
THEGSKCULTUREAtGSK,greatemphasisisplacednotonlyonwhatwemustachieveasacompany,butalsoonhowwedeliverourachievements.
OurcultureissummedupintheGSKSpiritwhichdefinesthequalitiesweexpectallouremployeestoembrace:performancewithintegrityentrepreneurialspiritfocusoninnovationasenseofurgencypassionforachievementDevelopingtheGSKcultureiscriticaltoenablingpeopletoreachtheirpotentialanddotheirbestwork.
Wethereforecarriedoutasurveyin2002of10,000managerstoassesshowwelltheSpiritandcultureisbeingadopted.
WesoughtviewsontheexperienceofworkingforGSK,includingbothwhatmanagersconsideredwasbeingdonewellandwhatareasneededfurtherwork.
Thesurveyresultsweregenerallyverypositive,showingthatmanagerstakegreatprideinbeingpartofGSK.
Forexample,therewasoverwhelmingsupportforthestatementsthat"peopleinmydepartmentshowcommitmenttoperformancewithintegrity","mydepartmentisafocusedorganisationwithasenseofurgency"and"IwouldgladlyreferagoodfriendorfamilymembertoGSKforemployment".
ThesefindingsshowthatmanagersbelievethattheGSKSpiritisreflectedinthewaytheyandothersareworkingdaytoday.
Theresultsalsoraisedimportantareasforfurtherdevelopment.
Theseincludedconcernsaboutwhetherpeopleareabletoperformtotheirfullpotential,theextenttowhichmanagersareabletoactascoachestosupportdevelopment,andthedegreeofstaffinvolvementindecisionsthataffecttheirwork.
TheseissuesareallbeingaddressedbyGSK'sCorporateExecutiveTeam.
Forexample,aprogrammehasbeenputinplacetoreducecomplexityandbureaucracyinthecompanyandtostreamlineprocessestohelpfreeupmanagerstodotheirbestwork.
ValuingpeoplePeoplearethegreatestsinglesourceofcompetitiveadvantageforanycompany.
AtGlaxoSmithKline,webelievethatattracting,retainingandmotivatingtheverybestpeopleisthefoundationforourfuturesuccess.
21Thesurveyresultsweregenerallyverypositive,showingthatmanagerstakegreatprideinbeingpartofGSK.
HUMANRIGHTSGSKbelievesthatonhumanrightsissues,wecanleadbyexampleandtherebyinfluencethebehavioursandpracticesofothersthroughcleardemonstrationofourownvalues.
Ourmosteffectivecontributioncanbemadethroughpursuingpoliciesinourownoperationsthatrespecttherightsandinterestsofallthoseaffectedbyandinvolvedinourbusiness.
GSKsupportsandiscommittedtoupholdingtheUnitedNationsUniversalDeclarationofHumanRights26andthecorelabourstandardssetoutbytheInternationalLabourOrganization27.
During2002,wecarriedoutaninternalreviewwhichdemonstratedthat,whereverweoperateasanemployer,webelievewearecomplyingwiththeUniversalDeclarationofHumanRightsandthecoreconventionsoftheInternationalLabourOrganization,andaccordingtotheGuidelinesforMultinationalEnterprisessetbytheOECD28.
ConductedthroughtheHeadofHumanResourcesforeachcountry,thereviewwasalsousedtobuildawarenessandunderstandingofhumanrightsissues.
Alsoduringtheyear,webegantoputinplacebindingrequirementstoensurethatourmajorcontractorsandsuppliersadoptGSK'sstandardsonhumanrightsandcorelabourstandards.
DIVERSITYDiversityisabusinessimperativeforGSK;wearecommittedtotheprinciplesofequalityofopportunityandequaltreatment.
Weaimtohaveaworkforceandworkingenvironmentthatreflectsthediversityofbackground,culture,beliefsandcharacteristicsofthecommunitiesinwhichweoperate.
Wearethereforeembeddingthevaluesofdiversityandequaltreatmentintoourkeybusinessprocesses.
Foremployees,thismeansthatdiversitymeasuresareincludedinmanagerandemployeetraining,externalrecruitmentandinternalappointmentprocesses,performanceassessmentsandpayreviews,successionplanninganddevelopmentalassignments.
Forcustomersandstakeholders,itincludesthedevelopmentofmeasurestoreachtargetedcustomers,outreachprogrammesforspecificpatientgroupsandadvertisingthatreflectsthemanycommunitiesweserve.
Webelievethatourdiversitystrategywillshowclearprogressagainstthebaselinefigureswereportthisyear(seebelow).
Wewillreportchangesannually.
WiththeexceptionoftheUS(seeethnicitychart),wedonothavemeaningfuldataontheethnicityofouremployeesbecauseofthedifferentwaysethnicgroupsaredescribedindifferentcountriesand,insomecases,becauseoflegalrestrictionsoncollectingthesedata.
Wearefundamentallycommittedtotheprinciplesofequalityofopportunityandequaltreatment.
22BandsA&B*583(81%)134(19%)BandsC1-3**2708(70%)1159(30%)BandsC4&5***4409(65%)2343(35%)Total7700(68%)3636(32%)GLOBALSENIORMANAGEMENTPOPULATIONBYGENDER2002MenWomen*CorporateExecutiveTeamandVice-Presidents/SeniorVicePresidents**DirectorLevel***ManagerLevelETHNICITYOFUSEMPLOYEEPOPULATION,2002TotalUSemployees24,00019%PeopleofcolourCasestudyOurpromotionofdiversitywithinGSKhashadapowerfuleffectonthewaywethinkabouttheneedsofourcustomers.
23Ensuringthatourmedicinesbenefitthewidestpossiblenumberofpatientsisattheheartofourmissiontoenablepeopletodomore,feelbetterandlivelonger.
In2001,oneofGSK'sGeneralPharmasalesandmarketingunitsintheUSmadeitakeybusinessobjectivetoimproveaccesstoGSKmedicinestopatientsfromethnicminoritycommunities.
TheunitoperatesinapartofsouthernCaliforniawithaparticularlyhighpopulationofVietnamese,Koreans,Armenians,CentralAmericansandMexicans.
Thesalesteamshadspecifictrainingonculturalawarenesstoimprovetheirunderstandingoftheircustomersandtheirparticularneeds.
Asaresult,doctorsarebetterabletouseGSKproducts,withbenefitsforindividualpatientsandforthesecommunities.
Buildingonthissuccess,culturalawarenesstrainingwasextendedtoallsalesgroupsacrosstheUSduring2002.
ThisapproachisalsobeingusedinGSK'sUSPharmamarketingdepartmentstoincreasemulticulturalawarenessandunderstandingrelatingtoeachofourbrands.
Inaddition,throughourmulti-languagepatienteducationprogramme,wearesupportingUShealthcareprofessionalsinraisingawarenessofdiseasesanddiseasemanagementamonggroupswithlimitedcommandofEnglish.
Diseaseeducationmaterialsonasthma,migraine,rhinitisanddepressionarebeingprovidedbyGSKsalesrepresentativesinanumberoflanguagesincludingSpanish,Chinese,Vietnamese,KoreanandRussian.
GSKhasacomprehensiveprogrammetocharacterisethephysicalandchemicalproperties,environmentalfateandeffects,andoccupationalhealtheffectsofourproductsandchemicalprocesses.
24Althoughmanyofthecontractorsonoursitesdonotworkunderourdirectsupervision,theirsafetyisasimportantasthatofouremployees.
Weapplythesamestandardstothem,andmonitortheirhealthandsafety.
ForexternalcontractorsworkingforGSK,thelosttimeinjuryandillnessratewassimilartotherateforourownemployees.
WeimproveourEHSperformancebyhavingstrongEHSmanagementsystemsandprogrammesinplace.
Fourexamplesaregivenbelow.
EHSinformationforourproductsandprocessesGSKhasacomprehensiveprogrammetocharacterisethephysicalandchemicalproperties,environmentalfateandeffects,andoccupationalhealtheffectsofourproductsandchemicalprocesses.
Thisinformationhelpsusto:designandoperateourproductionandcontrolsystemstoprotectouremployeesandthecommunitiesinwhichweoperate.
informouremployeesandthepublicaboutthehazardsofmaterialstohelpthemunderstandhowtohandlethemsafely.
Wehaveacomprehensiveframeworkofenvironmental,healthandsafetyprogrammesthatprovidethestructureforourapproach.
ThisisbasedonEHSStandardsthatapply,withoutexception,toallofoursitesaroundtheworld.
Environmentalsustainabilityisthebasisofourenvironmentalprogrammes.
Afteraddressingthepotentialforadverseimpactsfromourwastes,ourapproachtoachievingsustainabilityistofocusonimprovingtheefficiencyofourmanufacturingprocessestominimisethematerialsusedandwastegenerated,andthentooptimisetheuseofrenewablerawmaterials.
Ouroccupationalhealthandsafetyprogrammesfocusonprotectingandenhancingthehealthandsafetyofouremployees,reflectingthevalueweplaceonpeople.
IMPROVEMENTTARGETSOurEHSperformancetargetsaresetagainstbaselineperformancein2001,thefirstfullyearofGSK'soperations,andaretobeachievedbytheendof2005.
Forenvironmentalemissions,company-widetargetshavebeensetbyconsolidatingindividualsitetargets.
Ourhealthandsafetytargetistoreducelosttimeinjuriesandillnessesby15percenteachyearto2005,fromabaselineratein2001of0.
43losttimeinjuriesandillnessesforeach100,000hoursworked.
Preliminarydatafor2002indicatethatwewillmeetthistargetfortheyear.
Finalverifiedresultswillbeonourwebsite,www.
gsk.
com.
Asaresponsibleglobalcitizen,GlaxoSmithKlinestrivestopreservetheenvironmentandprotectthehealthofpeoplewhoworkforus.
Environment,healthandsafety25OneofGSK'sdrypowderdevicesff19981999200020012005%of2001baseline200150100500YearEXAMPLESOFENVIRONMENTALPERFORMANCEIMPROVEMENTSContractmanufacturersGSKusescontractmanufacturersinanumberofcountriestosupplycertainproductsforlocalmarketsand,inafewcases,forspecialistprocessesortechnologies.
Theyareanintegralpartoftheproductsupplychainsoweworkwiththemtopreventadverseeventsandensurethereliabilityofproductsupply.
ToensurethatthesecompaniesaremanagingEHSrisksandimpactsresponsibly,conformancewithGSKrequirementsandlegislationisassessedthroughaprogrammeofEHSauditsconductedbyourEHSGlobalAuditTeam.
TheauditscovergeneralmanagementofEHSandcontrolofkeyrisksandimpacts.
Areasforimprovementarehighlightedtothecontractmanufacturerandprogressismonitored.
In2002,16keycontractmanufacturers/supplierswereassessed.
Ozonedepletionandchlorofluorocarbon(CFC)elimination–Metereddoseinhalers(MDIs)arethemostcommonwaythatasthmaticsreceivetheirmedication.
However,manyMDIsuseaspropellantsCFCsthatareozonedepletingandglobalwarminggases.
CurrentlyGSKhasanextensiveplancontainingover10,000milestonestoeliminateCFCsfromourMDIs.
Progressisexcellentwith68percentoftheactionscompleted.
In2002,forthefirsttimesincethetransitionbegan,GSKmanufacturedover100millionnon-CFCMDIsandlaunchedourfirstnon-CFCMDIintheUS,CFC-freeVentolin.
CoupledwithofferingawidechoiceofdrypowderdevicesweareconfidentinourabilitytotransitionawayfromCFCs.
WethereforebelievethattheMontrealProtocol'essential-use'exemptionthatallowsthemanufactureofCFCsforsalbutamol/albuterol(theactiveingredientinVentolin)MDIs,andthemarketingofsalbutamol/albuterolMDIscontainingCFCs,isnolongernecessary.
ContaminatedlandWearecurrentlystudyingoractivelycleaningup31sitesthatareclassedascontaminatedland.
Wearealsoremediatinganumberofourformermanufacturingsitesinpreparationfortheir26decommissioningorsale.
GSKhasspentover100milliontodateandexpectstospendabout30milliononfurtherremediationatexistingsites.
Whendesigningandimplementingremediationprojects,weworkwithgovernmentagenciesandlocalcommunitiestousethebesttechnologiesavailabletocleanupthelandtoallowreturntootherusesuchascommunityparklands.
Atmostofthesesites,landhasbeencontaminatedduetopaststorageanddisposalpractices,includingpoorcontainmentoraccidentalreleasesatcommercialdisposalsites.
Theglobalstandardsandsystemswenowhaveinplacetocoverallphasesofwastemanagementaredesignedtopreventfutureincidentsthatcouldcontaminateland.
ENVIRONMENTALPERFORMANCEBothGSK'sheritagecompaniesrealisedthebenefitofsettingtargetstoimproveenvironmentalperformance.
Improvementprojectswerestartedinthe1980sandwillcontinueintothefuture.
Thechartbelowillustratestheimprovementsalreadyachievedinairemissions(VOC),wastewaterdischarges(COD)andhazardouswastedisposedinthethreeyearsleadinguptotheGSKbaselineof2001.
ThemostrecentperformancedataagainstEHStargetsareavailableonourwebsite29.
FiguresnormalisedbysalesVOC(VolatileOrganicCompoundsemittedtoair)COD(ChemicalOxygenDemandinwastewater)HWD(HazardousWasteDisposed)KeyTARGETCasestudyInnovativeapproachesdeliveredanexcellentsafetyrecordduringtheconstructionofGSK'snewHorlicksplantinIndia.
27GSKhasrecentlycompletedbuildinganewfactoryatSonepatinthenorthofIndiatomeetgrowingdemandinthecountryforHorlicks,oneofGSK'smostpopularnutritionaldrinks.
Theprojectinvolvedover17,000constructionpersonnelandatotalof13.
4millionhoursofworkover3.
5years.
Atitspeak,therewere1,900workersonthesiteatonetime.
Mostworkerswereonsiteforlessthan60days,soensuringthatthechangingworkforcewasmadeawareofthesafetyandhealthissueswasasignificantchallenge.
Healthandsafetyweregivenprioritywhenconstructionwasplanned,andappropriateprogrammeswereputinplaceonthesite.
Theseincludedprovidinga24-hoursitehealthfacility,sothatinjuriesandillnessescouldbetreatedearlyandworkersdidnotneedtoleavethesitefortreatment.
Inductiontrainingfornewworkersemphasisedsafety,inspectorsmonitoredhigh-riskareasonthesite,andweeklytalksonsafetytopicsandspecialtrainingprogrammesforscaffolderswereheld.
ThiswasanewapproachforamajorgreenfieldsiteconstructionprojectinIndia,wherehistoricallyprojectsofthistypedonotinvolveahighlevelofattentiontohealthandsafety,andwhereformalsafetytrainingisnotcommon.
Asaresultoftheseinitiatives,accomplishedinpartnershipwithconstructionmanagementandsubcontractcompanies,Sonepatreturnedoneofthebestlost-timeaccidentfiguresseeninprojectswithinGSKanditslegacycompanies.
Benefitsofthehealthandsafetyplanningweredemonstratedimmediatelyandimprovedoverthecourseoftheprojectsothatthelast6.
6millionhourswereworkedwithoutanylost-timeinjuriesorillnesses.
Alastingbenefitofthisprojectisthefutureapplicationoflessonslearnedincreatingasafetyculture.
Thisprojectwonthe2002EHSInitiativeAwardwhichissponsoredbytheChiefExecutiveOfficer.
Itwasselectedbyapanelofjudgesrepresentingacademia,government,NGOsandGSK'sBoardofDirectors.
Highstandardsofhonestyandintegrityarevitaltothesuccessofourbusiness.
"Performancewithintegrity"istheprinciplebywhichweaimtoliveandworkatGSK.
28CORPORATEETHICSANDCOMPLIANCEGSKiscommittedtooperatingwithinthelawandtothehighestethicalstandards.
Thehealthcareindustryishighlyregulatedandthediscovery,development,manufacturingandmarketingofmedicinesarecomplexprocesses.
Thus,weaimtobuildadherencetohighstandardsintotheeverydaymanagementprocessesoftheseactivities.
Formalcompanypolicesandproceduressetouttheexpectedstandardsofconduct,buteffectivecommunicationandtrainingonthesestandards,followedbyregularmonitoringandperiodicreviewofworkoutput,arecritical.
Whilelawyersandcomplianceofficersarecloselyinvolvedinestablishingandcommunicatingstandards,GSKemphasisesthepersonalresponsibilityofemployeesandtheirlinemanagersforensuringthatallemployeesobservetheseprinciplesintheireverydaywork.
Tosupportthisweundertakeethicstrainingthroughcomputer-basedsessionsandinteractivediscussions.
TheCorporateEthicsandCompliancefunctionatGSKisresponsibleforsupportingthedevelopmentandimplementationofpracticesthatfacilitateemployees'compliancewithlawsandcompanypolicy.
SpecialistcomplianceofficerssupportourmainoperationsofPharmaceuticals,ConsumerHealthcare,R&DandManufacturing.
Aninternalcontrolframeworkintegratesethicsandcompliancewiththeday-to-daymanagementoftheGroup.
Thisframeworksupportslinemanagementintheidentificationandmitigationofsignificantrisks,amongwhicharepotentialcompliancefailures.
BusinessethicsandintegrityGlaxoSmithKline'sCodeofConductlaysouttheprinciplesthatthecompanyvaluesandthatemployeesshouldapplyintheirdailywork.
ItistheresponsibilityofeachemployeetoimplementtheCodetosustainthetrustandconfidenceofallGSK'sstakeholders.
29TheframeworkincludesaRiskOversightandComplianceCouncil,aswellassectorandotherbusinessunitriskmanagementandcomplianceboards.
TheRiskOversightandComplianceCouncilandboardsassistintheidentificationandmitigationofrisksandprovideguidanceonriskmanagementinitiativesatthecorporateandbusinessunitlevels.
TheRiskOversightandComplianceCouncilreportstotheAuditCommitteeoftheGSKBoardandtheChiefExecutiveOfficer,andwillalsoreporttotheCorporateExecutiveTeam.
ThereportinglinetotheAuditCommitteeprovidesamechanismforbypassingtheexecutivemanagementifirregularitiesareeveridentified.
GSKRISKMANAGEMENT&COMPLIANCEFRAMEWORKGSKBOARDCEOCETBUSINESSANDFUNCTIONHEADSRISKOVERSIGHTANDCOMPLIANCECOUNCIL(ROCC)BUSINESSUNITORFUNCTIONALRISKMANAGEMENTANDCOMPLIANCEBOARDSBUSINESSANDFUNCTIONALGROUPSPOTENTIALRISKSANDRISK-GENERATINGACTIVITIESANDFUNCTIONSAuditCommitteeCorporateSocialResponsibilityCommittee30GSKPOLICIESTheGSKCodeofConductandallGSKpoliciesareavailableonourinternalwebsite.
In2002,aguidetobusinessconductwaspublishedontheinternalwebsitetosupportemployees'understandingandimplementationofthesestandards.
Theguidesummarisespoliciesandexplainsthecompany'sexpectationsonbusinessethicsandgoodbusinessconduct.
NOTIFICATIONSYSTEMSConfidentialIntegrityHelpLinestocomplianceofficersareavailableforemployeestoreportconcernstheyfeelarenotbeingdealtwithadequatelythroughthenormalmanagementsystem.
TheseHelpLinesareavailabletoemployeesintheUKandUS,reachingabouthalfthetotalGSKworkforce.
Otheremployeescantakeadvantageofe-mailaccesstoacomplianceofficer,orcanreportconcernsthroughaconfidentialpostofficeboxmaintainedbyCorporateEthicsandCompliance.
TheHelpLinesareprimarilyusedforconsultationsandbyemployeestoaskquestions.
Asaresult,thenumberofcallersandinquiriesreceivedbycomplianceofficerstendstoincreaseinresponsetotrainingortochangesinorissuanceofnewpolicies.
Activitylevelsreflectgreaterawarenessofpoliciesandlegalrequirementsratherthantrendsinunacceptablepractices.
Responselevelsindicatethattheexistenceofthesystemsandtheirpurposearewellunderstood.
Confidentialtoll-freelinestocomplianceofficersareavailableforemployeestoreportconcerns.
CasestudySeniormanagersinGSKareexpectedtoleadbyexamplebyworkinginlinewiththeCodeofConductandotherGSKpoliciesandinsupportingtheirstafftodothesame.
Toensuretheirunderstandingofthisresponsibility,in2002GSKintroducedacertificationprocessaroundtheworldformanagersatthevice-presidentlevelandabove.
CertificationrequiresthesemanagerstosignastatementconfirmingtheirawarenessoftheirobligationstoimplementthecompanyCodeofConductandpolicies.
Thisincludesconfirmingthat:Theyknowtheyarepersonallyobligedtocomplywithapplicablelaws,regulations,andGSK'scorporateandlocalpoliciesandprocedures.
Theyaccepttheirresponsibilitytoputinplaceappropriatemeasurestoensurethatthepeopleundertheirsupervisionareawareoftheirownobligations.
31Allpeopleundertheirsupervisionhavereceivedcopiesof,orhaveaccessto,theGSKCodeofConductandotherGSKpolicies,andunderstandtheirresponsibilities.
In2002,around700managers–allthoseatvice-presidentlevelandabove–completedcertifications.
WebelievethisprocesswillfurthersupportthedisseminationandawarenessofGSKethicalstandardsandtheCodeofConductandtheirimportancetothousandsofotherGSKemployeeswho,inthecourseoftheirdailyactivities,mustworkinlinewiththelawandGSKpolicies.
fffGSKBOARDCEOCETMEMBERCSRCO-ORDINATION&REPORTINGCSRCOMMITTEE32ManagementofCSROurcorporateandsocialresponsibility(CSR)activities,includingthosecoveredinthisreport,aremanagedinthemostappropriatefunctionsintheorganisationratherthanthroughacentraldepartment.
Webelievethisisthemosteffectiveapproachtomanagingtheissuesbecausetheyremainanintegratedpartoftheeverydayoperationofthebusiness.
Tofacilitatepolicydevelopment,implementationandcommunication,across-functionalteamwasestablishedatthebeginningof2002toensureacomprehensiveandco-ordinatedapproach.
Theteamismadeupofrepresentativesfromthekeybusinessareaswhoensurethatpoliciesareinplaceandmechanismsexistfortheirimplementationandmonitoring.
Therepresentativesalsocontributetoreportingprogressthroughthisreportandinotherways,forexamplethroughconferencepresentationsandonourwebsite.
Duringtheyearthiscross-functionalteamdevelopedindicatorsthatwillsupportreportingonkeyissues.
Indeterminingtheindicators,weaimtostrikeabalancebetweenthedesiresofourstakeholdersforgreatertransparencyaboutouroperationswiththerealitiesandcostsofrunningthebusiness.
Contributingtoimprovingpeople'slivesasaresponsiblecorporatecitizenisanintegralandestablishedpartofourbusinesspractice.
Wealsobelievethatstakeholderdiscussiononanythingthatrequiresspecialistknowledgeisbestundertakenbythosewithsuchexpertise.
Hencetheteamrepresentativesdiscussissuesdirectlywiththosewhohaveexpressedaninterestorconcern,andcentralco-ordinationmeansthatbroaderissuesarebroughttotheattentionofthecross-functionalteam.
GSKhasaprocessinplaceforidentifying,evaluatingandmanagingsignificantbusinessrisks,andthisincludesreputationalandcorporateresponsibilityissues.
OurriskmanagementprocessaccordswiththeTurnbullguidanceandourformalriskassessmentisupdatedatleastonceayear.
TheRiskOversightandComplianceCouncil(seepage29)coordinatesinternalcontrolandriskmanagementactivitiestoensureeffectivemanagementofsignificantrisks.
Duringtheyear,theCSRcommitteeofNon-ExecutiveBoardmembersgaveadviceonhowwereportouractivities,andhadspecificinputintoourapproachtocommunityinvestment,environment,healthandsafetyandhumanresourcespoliciesincludingdiversityandhumanrightsissues.
GlobalGovernmentAffairs&PublicPolicyMEDICINESFORTHEDEVELOPINGWORLDR&D–DISEASESOFTHEDEVELOPINGWORLDETHICALISSUESINR&DCARINGFORTHEENVIRONMENTBUSINESSETHICSDEVELOPINGOUREMPLOYEESSUPPORTINGHUMANRIGHTSCOMMUNITYINVESTMENTCROSS-FUNCTIONALMANAGEMENTOFCSRACTIVITIES1www.
gsk.
com/ser/2001/ser01/CSR.
pdf2www.
polioeradication.
org/3www.
gsk.
com/press_archive/press_10032001.
htm4www.
togetherrx.
com/5www.
gsk.
com/about/developing_world.
htm6www.
niaid.
nih.
gov/factsheets/hvtn.
htm7www.
who.
int/inf-pr-2001/en/pr2001-10.
html8www.
gsk.
com/about/nfp_pricing_guide.
htm9www.
gsk.
com/press_archive/press_09052002.
htm10www.
gsk.
com/community/about.
htm11www.
gsk.
com/filariasis/index.
htm12www.
gsk.
com/positiveaction/index.
htm13www.
gsk.
com/press_archive/press_11282002.
htm14www.
gsk.
fr/gsk/fond/mp.
html15www.
gsk.
com/malaria/index.
htmWebreferencesOurcorporatewebsitecanbefoundatwww.
gsk.
com.
Websitescitedinthisreport:Ifyouhaveanyquestionsorviewstoshare,pleasecontactusatcsr.
contact@gsk.
comorwritetousat:CSRGlobalPublicPolicyGlaxoSmithKline980GreatWestRoadBrentfordMiddlesexTW89GSUKDesignconsultancybysalterbaxter.
ProductnamesthroughoutthispublicationareindicatedinitalicsandaretrademarksofGlaxoSmithKlineplc,itssubsidiariesorassociatedcompanies.
PrintedintheUKbyStIvesWesterhamPress.
Thepaperusedintheproductionofthisdocumentismadefrompulpsharvestedfromsustainableforests,alsousingsawmillresiduesandforestthinnings.
Itiselementalchlorine-free.
CORPORATESOCIALRESPONSIBILITYCOMMITTEE16www.
gsk.
com/community17www.
projecthope.
org/18www.
pqmd.
org19www.
gsk.
com/press_archive/press_11172001.
htm20www.
ic.
ac.
uk/templates/text_3.
aspP=345321www.
corporate-citizenship.
co.
uk/community/lbg.
asp22www.
rds-online.
org.
uk/news.
html23www.
aaalac.
org24http://science.
gsk.
com/about/animal-research.
htm25www.
phrma.
org/publications/quickfacts/20.
06.
2002.
428.
cfm26www.
un.
org/Overview/rights.
html27www.
ilo.
org/public/english/standards/decl/declaration/text/index.
htm28www.
oecd.
org/pdf/M000015000/M00015419.
pdf29www.
gsk.
com/ser/2001/ser01/ehs.
pdfDrMichèleBarzachANon-ExecutiveDirectorofGlaxoSmithKline,DrBarzachisamemberoftheInternationalCooperationHighCouncil,ChairmanoftheBoardofEquilibresetPopulationsandDirectoroftheBoardofProjectHope.
Internationalconsultantinhealthstrategy,shewasformerlyFrenchMinisterofHealthandFamily.
DonaldMcHenryANon-ExecutiveDirectorofGlaxoSmithKlineandchairmanoftheCorporateSocialResponsibilityCommittee.
MrMcHenryisaDistinguishedProfessorinthePracticeofDiplomacyattheSchoolofForeignServiceatGeorgetownUniversityandisPresidentoftheIRCGroup,LLC.
SirChristopherHoggSirChristopheristheNon-ExecutiveChairmanofGlaxoSmithKline.
HeisNon-ExecutiveChairmanofReutersGroupPLC,amemberoftheSupervisoryBoardofAirLiquideS.
A.
andChairmanofTheRoyalNationalTheatre.
DrLucyShapiroANon-ExecutiveDirectorofGlaxoSmithKline,DrShapiroisLudwigProfessorofCancerResearchintheDepartmentofDevelopmentalBiologyandDirectoroftheBeckmanCentreforMolecularandGeneticMedicineattheStanfordUniversitySchoolofMedicine.
www.
gsk.
com